Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 9, 2006

Primary Completion Date

September 6, 2016

Study Completion Date

September 6, 2016

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
OTHER

high performance liquid chromatography

Performed on serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples

OTHER

pharmacological study

Serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples

PROCEDURE

radionuclide imaging

1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post Y-90 anti-CEA antibody infusion

PROCEDURE

single photon emission computed tomography

2 days and 3-5 days post antibody infusion

RADIATION

yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A

Dose escalation from 12 mCi/m2 through 18 mCi/m2 increasing by 2 mCi/m2 with each escalation

Trial Locations (1)

91010-3000

City of Hope Comprehensive Cancer Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT00645060 - Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter